ERNEST G THOMPSON JR
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- BAKER, LA
- NPI
- 1841212610
- Received
- $14,053 in 661 records, 2019 to 2025
- As principal investigator
- $2,040,236 of research payments to others in 122 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 93 | $2,205 |
| 2024 | General payment | 58 | $1,219 |
| 2023 | General payment | 79 | $1,659 |
| 2022 | General payment | 89 | $1,711 |
| 2021 | General payment | 120 | $2,579 |
| 2020 | General payment | 104 | $2,092 |
| 2019 | General payment | 118 | $2,585 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 659 | $14,030 |
| Travel and Lodging | 1 | $17 |
| Education | 1 | $6 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | Abbott Laboratories | $72 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-12-12 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-05 | Vanda Pharmaceuticals Inc. | $36 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-04 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-02 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-01 | Exact Sciences Corporation | $17 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-11-24 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-24 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-18 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-11-17 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-17 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-11 | Otsuka America Pharmaceutical, Inc. | $122 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-10 | Lundbeck LLC | $19 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-06 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-05 | Ardelyx, Inc. | $20 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-11-03 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-10-28 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $113 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-28 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-21 | Dexcom, Inc. | $18 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-10-21 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-07 | Bayer Healthcare Pharmaceuticals Inc. | $7 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-02 | E.R. Squibb & Sons, L.L.C. | $8 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-01 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-26 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-25 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-18 | Axsome Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-15 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-04 | Axsome Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-08-26 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-21 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $121 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-05 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-08-01 | Vanda Pharmaceuticals Inc. | $38 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-07-25 | Medtronic, Inc. | $22 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-07-22 | Kowa Pharmaceuticals America, Inc. | $15 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-07-21 | Axsome Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-17 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-15 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-10 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-07-10 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-07-08 | GENZYME CORPORATION | $43 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-07 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-24 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-06-23 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-06-20 | Otsuka America Pharmaceutical, Inc. | $22 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-17 | Axsome Therapeutics, Inc. | $26 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-17 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-06-17 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-06-12 | Abbott Laboratories | $37 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-06-07 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-04 | Ardelyx, Inc. | $18 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-05-28 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-05-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-20 | Ardelyx, Inc. | $6 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-05-19 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-05-14 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-05-07 | Ardelyx, Inc. | $22 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-05-07 | Ardelyx, Inc. | $11 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-04-30 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-04-25 | Vanda Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-04-25 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-04-23 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-04-22 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-04-21 | Astellas Pharma US Inc | $17 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2025 | |
| 2025-04-10 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-04-09 | Ardelyx, Inc. | $21 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-04-08 | Abbott Laboratories | $40 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-04-01 | Bayer Healthcare Pharmaceuticals Inc. | $7 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-20 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage (4 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-03-19 | Abbott Laboratories | $3 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-03-12 | Ardelyx, Inc. | $19 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-03-12 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-03-11 | Bayer Healthcare Pharmaceuticals Inc. | $6 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-10 | Axsome Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-26 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-02-19 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2025 | |
| 2025-02-18 | SHIELD THERAPEUTICS INC | $19 | Food and Beverage | In-kind items and services | ACCRUFER Drug, Hematology | 2025 | |
| 2025-02-11 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-02-11 | Bayer Healthcare Pharmaceuticals Inc. | $2 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-30 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-29 | Ardelyx, Inc. | $23 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-01-28 | Bayer Healthcare Pharmaceuticals Inc. | $6 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-01-07 | Axsome Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-01-06 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-01-03 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2024-12-12 | Insulet Corporation | $21 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-10 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-12-03 | Ardelyx, Inc. | $17 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-11-21 | Vanda Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2024 | |
| 2024-11-19 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-11-11 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-11-07 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-10-29 | GlaxoSmithKline, LLC. | $22 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-10-29 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-10-17 | Insulet Corporation | $20 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-07 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-09-25 | Dexcom, Inc. | $24 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-09-24 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-09-17 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage (4 payments) | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-09-16 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-09-16 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-09-10 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-09-05 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-08-22 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-08-20 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-08-20 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-08-19 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-08-06 | Astellas Pharma US Inc | $16 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2024 | |
| 2024-08-01 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-23 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-07-16 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-07-08 | Neurocrine BioSciences, Inc. | $27 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-25 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-06-24 | Dexcom, Inc. | $49 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-06-19 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-13 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-06-10 | Astellas Pharma US Inc | $16 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2024 | |
| 2024-06-06 | Exact Sciences Corporation | $15 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-06-05 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-03 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-05-30 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-05-16 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-14 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-05-14 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-05-07 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2024 | |
| 2024-05-02 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-04-25 | Exact Sciences Corporation | $15 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-04-24 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-04-23 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-03-28 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-03-26 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-03-22 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-03-19 | Mannkind Corporation | $16 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2024 | |
| 2024-03-11 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-03-07 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2024 | |
| 2024-02-29 | Astellas Pharma US Inc | $14 | Food and Beverage | In-kind items and services | Myrbetriq Drug, Urology | 2024 | |
| 2024-02-20 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2024 | |
| 2024-02-06 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2024 | |
| 2024-02-05 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-24 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-24 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-10 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2024 | |
| 2024-01-09 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2023-12-08 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-12-07 | Astellas Pharma US Inc | $121 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-12-04 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-11-29 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-14 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-11-14 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2023 | |
| 2023-11-13 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-11-09 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-11-06 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-11-06 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-10-26 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-10-25 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-10-25 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VIBERZI Drug, GASTROENTEROLOGY | 2023 | |
| 2023-10-18 | Teva Pharmaceuticals USA, Inc. | $110 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-10-16 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-10-10 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-10-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-10-05 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-09-25 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-09-19 | PFIZER INC. | $33 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2023 | |
| 2023-08-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-08-24 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-22 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-08-21 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2023 | |
| 2023-08-18 | Daiichi Sankyo Inc. | $13 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2023 | |
| 2023-08-17 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-08 | Embecta Corp. | $16 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-08-03 | Astellas Pharma US Inc | $16 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-08-02 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-07-31 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-07-25 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-07-19 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2023 | |
| 2023-07-13 | Embecta Corp. | $15 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-07-08 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-07-06 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-06-28 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-06-15 | Embecta Corp. | $16 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2023 | |
| 2023-06-14 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-06-13 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-06-08 | Astellas Pharma US Inc | $15 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-06-01 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-05-23 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-05-17 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-05-09 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-04-28 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-04-25 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-04-25 | Xeris Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2023 |
The latest 200 records of 661.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Boehringer Ingelheim International GmbH | Southern Clinical Research-Louisiana | $182 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | Southern Clinical Research-Louisiana | $259 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Southern Clinical Research LLC | $10,000 | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Southern Clinical Research LLC | $2,598 | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran | 2025 |
| 2025-09-08 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $13,354 | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and | 2025 |
| 2025-08-27 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $4,233 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2025 |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $54,221 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $26,285 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $16,198 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $10,100 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $148,048 | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Densit | 2025 |
| 2025-05-01 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $12,855 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 |
| 2025-02-04 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $64,793 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $32,377 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-01-29 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $8,750 | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the E | 2025 |
| 2025-01-27 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $64,430 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $27,259 | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $43,050 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $13,185 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study t | 2025 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $470 | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the E | 2024 |
| 2024-12-23 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $232 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-12-06 | Chiesi USA, Inc. | Southern Clinical Research LLC | $1,344 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2024 |
| 2024-12-03 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $8,156 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-09-25 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $4,329 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study t | 2024 |
| 2024-07-31 | Chiesi USA, Inc. | Southern Clinical Research LLC | $956 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2024 |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $14,105 | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2024 |
| 2024-06-07 | Chiesi USA, Inc. | Southern Clinical Research LLC | $2,916 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2024 |
| 2024-05-08 | Chiesi USA, Inc. | Southern Clinical Research LLC | $3,829 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2024 |
| 2024-04-23 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $232 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-04-19 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $92,768 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 |
| 2024-04-11 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $1,932 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-02-02 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $8,955 | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneo | 2024 |
| 2024-01-25 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $20,000 | A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Mo | 2024 |
| 2024-01-23 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $308 | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a | 2024 |
| 2024-01-15 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $19,699 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2024 |
| 2024-01-02 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $54,681 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-01-02 | Novartis Pharmaceuticals Corporation | SOUTHERN CLINIC RESEARCH CLINIC | $182,147 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $757 | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneo | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $793 | A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate | 2023 |
| 2023-12-27 | Chiesi USA, Inc. | Southern Clinical Research LLC | $1,345 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-11-27 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $1,218 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2023 |
| 2023-09-19 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $308 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2023 |
| 2023-08-24 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $36,483 | A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Mo | 2023 |
| 2023-08-23 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $8,764 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study t | 2023 |
| 2023-06-30 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $26,241 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-05-30 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,000 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2023 |
| 2023-05-30 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,001 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2023 |
| 2023-05-30 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,615 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2023 |
| 2023-05-25 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $48,864 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-04-18 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $84,330 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-03-31 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $10,067 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-03-30 | Chiesi USA, Inc. | Southern Clinical Research LLC | $10,000 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-03-28 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $17,344 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-03-20 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $1,526 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2023 |
| 2023-03-15 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $3,262 | A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate | 2023 |
| 2023-02-24 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $3,079 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2023 |
| 2023-02-22 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $3,554 | A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Effi | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $47,044 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $25,192 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2023 |
| 2023-01-25 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $14,433 | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneo | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $384 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2023 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $820 | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneo | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $1,203 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2022 |
| 2022-12-20 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $742 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2022 |
| 2022-07-27 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $15,626 | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneo | 2022 |
| 2022-05-05 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,653 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2022 |
| 2022-04-25 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $2,240 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2022 |
| 2022-04-21 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,708 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2022 |
| 2022-03-23 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $5,385 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2022 |
| 2022-03-23 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,207 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2022 |
| 2022-03-23 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,241 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2022 |
| 2022-02-01 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research, Llc | $2,240 | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2022 |
| 2022-01-28 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $23,882 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2022 |
| 2022-01-15 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $35,629 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2022 |
| 2022-01-11 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $20,780 | A 12-WEEK RANDOMIZED, PARTICIPANT-AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EXPLORE THE EFFI | 2022 |
| 2022-01-06 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $106,994 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2022 |
| 2022-01-01 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $861 | A 24 WEEK MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL | 2022 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $3,842 | A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet | 2021 |
| 2021-11-22 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $1,011 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-09-17 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $1,500 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2021 |
| 2021-09-17 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $7,500 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2021 |
| 2021-09-01 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $10,083 | A 12-WEEK RANDOMIZED, PARTICIPANT-AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EXPLORE THE EFFI | 2021 |
| 2021-08-30 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $1,942 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-08-26 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $284 | Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficac | 2021 |
| 2021-07-28 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $965 | Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficac | 2021 |
| 2021-07-27 | Teva Pharmaceuticals USA, Inc. | Southern Clinical Research LLC | $733 | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficac | 2021 |
| 2021-07-26 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $1,011 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-07-26 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $5,310 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-07-07 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $2,600 | Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficac | 2021 |
| 2021-06-23 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $1,011 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-06-23 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $1,275 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-06-21 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $4,161 | Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficac | 2021 |
| 2021-05-14 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $13,335 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2021 |
| 2021-02-11 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $11,193 | A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet | 2021 |
| 2021-02-02 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $5,500 | A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of fin | 2021 |
| 2021-01-15 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $52,582 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2021 |
| 2021-01-06 | Novartis Pharmaceuticals Corporation | Southern Clinical Research | $76,968 | A 24 WEEK MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL | 2021 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $2,166 | A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | SOUTHERN CLINICAL RESEARCH, LLC | $24 | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of | 2020 |
| 2020-07-21 | Bayer Healthcare Pharmaceuticals Inc. | Southern Clinical Research Llc | $3,000 | Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficac | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Baker, LA, county East Baton Rouge Parish, LA, state Louisiana; placed by its city name.
| Measure | Place (city or town) Baker, LA | County East Baton Rouge Parish, LA | State Louisiana |
|---|---|---|---|
| Population B01003 | 12,253 | 452,938 | 4,611,961 |
| Population, 2020 census P1 | 12,455 | 456,781 | 4,657,757 |
| Median age B01002 | 33.5 | 34.1 | 38.0 |
| Under 18 B01001 | 26.3% | 22.7% | 23.5% |
| 65 and over B01001 | 11.3% | 15.3% | 16.7% |
| Households B11001 | 4,292 | 177,295 | 1,804,780 |
| Foreign born B05002 | 0.9% | 7.1% | 4.9% |
| Median household income B19013 | $54,750 | $63,071 | $60,756 |
| Median family income B19113 | $62,483 | $85,206 | $79,407 |
| Per capita income B19301 | $23,746 | $38,736 | $35,038 |
| Poverty rate B17001 | 29.8% | 19.6% | 18.9% |
| Unemployment rate B23025 | 16.6% | 7.7% | 6.3% |
| Civilian labor force B23025 | 6,138 | 227,785 | 2,148,164 |
| Mean commute (minutes) B08013 | 24.3 | 23.6 | 25.7 |
| Bachelor's degree or higher B15003 | 20.6% | 38.5% | 27.0% |
| Housing units B25001 | 5,009 | 206,591 | 2,108,902 |
| Owner-occupied B25003 | 69.9% | 59.3% | 67.4% |
| Renters B25003 | 30.1% | 40.7% | 32.6% |
| Median home value B25077 | $157,900 | $248,800 | $216,500 |
| Median gross rent B25064 | $993 | $1,147 | $1,064 |
| White, not Hispanic B03002 | 10.0% | 41.6% | 55.7% |
| Black B03002 | 87.0% | 43.6% | 30.5% |
| Hispanic or Latino B03002 | 1.7% | 6.9% | 7.2% |
| Asian B03002 | 0.0% | 3.3% | 1.7% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.4% |
Economy now FRED unemployment 4.0% in Sep 2026 (4.2% a year earlier); per capita personal income $64,103 in 2025, up 28% in five years (+2.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Baker, LA.
Comments